ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS …

Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on ...

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. (1) Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference

The MarketWatch News Department was not involved in the creation of this content.-- Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was ...
The Bakersfield Californian

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide ...

Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177Lu-edotreotide arm vs. 14.7 months on everolimus armObjective response rate (ORR) was h ...
Taiwan News

Pyxis Tankers Announces Financial Results for the Three Months and Year Ended December 31, 2025

Pyxis Tankers Inc. (Nasdaq Cap Mkts: PXS), (the “Company”, “we”, “our”, “us” or “Pyxis Tankers”), an international diversified shipping company, today announced unaudited results for the three months ...